TIM3-Mediated Differentiation of IL-10-Producing CD25+ B Cells by Expanded Regulatory T Cells

The present and future of cell therapies for T1D

Project ACT series This article is part of a series exploring the different ways that Breakthrough T1D’s Project ACT (Accelerate Cell Therapies) will shape the future of cell therapies for type 1 diabetes (T1D). The next article in the series will discuss the progress of cell therapies in clinical trials. We’ve made major progress in the development of cell replacement therapies for type 1 diabetes (T1D) over the past couple of decades. We know …

TIM3-Mediated Differentiation of IL-10-Producing CD25+ B Cells by Expanded Regulatory T Cells

Cell-based immunotherapy utilizing regulatory T cells (Tregs) has recently advanced into clinical applications, demonstrating promising results in phase I/II trials to prevent transplant rejection and treat autoimmune diseases. We have completed a clinical trial in renal transplant patients in...